Entity family
Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.
This drug is selected. Its supporting articles are shown below.
…tor cabozantinib and the anti-PD-L1 immune checkpoint inhibitor nivolumab in patients with unresectable HCC ( NCT03299946). Major patholo…
…s, followed by curative-intent surgery and one year of adjuvant nivolumab. Primary study endpoints included multiomic profiling of surgic…
…II disease (93%). 55% (42/76) were treated with Ipilimumab plus Nivolumab (I/N), 41% (31/76) anti-PD1 monotherapy (PD1) and 4% (3/76) Niv…
…r model.Results The expression constructs for pembrolizumab and nivolumab demonstrated dose-dependent expression in vitro. The PD-1/PD-L1…
…23–34.Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cel…
…herapy, and 56.7% were stage IV at diagnosis. Patients received nivolumab (10%), pembrolizumab (70%), or ipilimumab/nivolumab combination…
… 32mos). We discover that after two cycles of chemotherapy with nivolumab long-term responders (PFS>12 months) have a tumor microenvironm…
…vo, supporting its evaluation in combination with nivolumab and ipilimumab.Methods This is an investigator-initiated, phase 1, dose-escala…
…2 and Flu 30 mg/m2 x 4 days, followed by a one-time infusion of IMA203 (1-10x 109 TCR T cells), and low-dose IL-2 (1 M IU QD x5 days, …
… be enrolled in the first stage. If ≥2 patients respond to NIVO+RELA, the study will continue enrollment for a total of 20 patients.…